This laboratory has previously identified a novel @entity41372 ( @entity41372 ) in @entity1 osteoblasts [Subramaniam et al. (1995): Nucleic Acids Res 23:4907-4912]. Using @entity41372 specific polyclonal antibody and immunoprecipitation methods in normal @entity1 fetal osteoblast cells (hFOB cells), we have now demonstrated that @entity41372 encodes a 72-kDa protein whose levels are transiently increased at as early as 2 h of TGF-beta treatment. Polarized confocal microscopic analysis of hFOB cells shows a nuclear localized @entity41372 protein in untreated cells under the conditions described under Methods. Interestingly, the levels of @entity41372 protein in the nuclei increase when the cells are treated with TGF-beta 1 for 2 h. In contrast, similar analyses of untreated @entity1 keratinocytes show a cytoplasmic localized @entity41372 protein that appears to be translocated to the nucleus after @entity274 treatment. Additional immunohistochemical studies have demonstrated that @entity41372 protein is expressed in epithelial cells of the placenta, breast, and pancreas, as well as in osteoblast cells of bone and selected other cells of the bone marrow and cerebellum with some cells showing a cytoplasmic localization and others a nuclear localization. All cells of the kidney display negative staining for this protein. Interestingly, a stage specific expression of @entity41372 protein is found in a dozen @entity0 biopsies, using immunohistochemistry. The cells in normal breast epithelium displays a high expression of @entity41372 protein, those in the in situ @entity189 display less than one-half of the levels, and those in the @entity189 show a complete absence of the @entity41372 protein. @entity41372 has been localized to chromosome 8q22.2 locus, the same locus as the genes involved in @entity2525 and @entity3052 and close to the @entity517 gene locus and a locus of high polymorphism in cancer biopsies. The correlation between the levels of @entity41372 protein and the stage of @entity0 , its prime location in @entity1 chromosome 8q22.2, and past studies with @entity3123 , suggests that @entity41372 may play a role in @entity5 suppressor gene activities, apoptosis, or some other regulatory function of cell cycle regulation.

Tissue, cell type, and XXXX stage-specific expression of a TGF-beta inducible early transcription factor gene.

@entity1 :: ('9606', 'Species') :: ['human'] @entity3123 :: ('MESH:C562463', 'Disease') :: ['pancreatic carcinoma'] @entity274 :: ('CHEBI:16240', 'Chemical') :: ['H2O2'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity517 :: ('4609', 'Gene') :: ['c-myc'] @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma', 'invasive carcinoma'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['acute myeloid leukemia'] @entity41372 :: ('7071', 'Gene') :: ['TIEG', 'TGF-beta inducible early gene'] @entity2525 :: ('MESH:D010022', 'Disease') :: ['osteopetrosis']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
